Cefiderocol Activity Against Resistant Enterobacterales

Carbapenem-resistant Enterobacterales (CRE) are difficult to treat because resistance can combine carbapenemase production, porin changes, target modification, and limited activity of β-lactam/β-lactamase inhibitor combinations. The reference study by Santerre Henriksen and colleagues addresses this problem through a large European surveillance analysis of cefiderocol activity, with particular attention to isolates resistant to meropenem and newer inhibitor combinations.

Its value is not simply the high percentage of susceptible isolates. The study combines direct comparative susceptibility testing with targeted PCR and whole-genome sequencing, allowing investigators to connect phenotype with resistance mechanisms. This design provides a practical framework for interpreting cefiderocol MIC results in the context of difficult-to-treat Enterobacterales.

Study Background and Research Question

European hospitals continue to encounter Enterobacterales with resistance to carbapenems and other β-lactams. The clinical problem is especially important for Klebsiella pneumoniae, Escherichia coli, and Enterobacter species, which commonly cause bloodstream, urinary, intra-abdominal, and respiratory infections. The study therefore asked two related questions: how active is cefiderocol against contemporary European Enterobacterales, and does its activity remain when isolates are resistant to meropenem or approved β-lactam/β-lactamase inhibitor combinations?

The authors also examined whether cefiderocol-resistant isolates carried recognizable genetic determinants. This mechanistic component matters because susceptibility percentages alone cannot explain why an isolate is resistant or predict whether a resistance phenotype will remain stable under antimicrobial exposure. The reference study was designed to address both the epidemiological and molecular dimensions of this question.

Key Innovation from the Reference Study

The principal innovation was the direct comparison of cefiderocol with multiple approved and developmental β-lactam/β-lactamase inhibitor combinations in a notably large, geographically distributed isolate collection. The investigators analyzed 1,909 isolates obtained from 49 hospital sites in six European countries during 2020, rather than relying on a small, single-center or intentionally selected resistance panel.

A second important design choice was the use of the high-dose meropenem resistance breakpoint, defined in the study as a meropenem MIC greater than 8 mg/L. This approach focused the analysis on isolates that would remain resistant despite meropenem doses available in clinical practice, making the comparison more relevant than a resistance definition based only on lower-dose exposure.

The study also evaluated cefiderocol as a single active compound rather than only as part of an inhibitor combination. That distinction clarifies its potential position among treatment options when β-lactamase-mediated resistance compromises other agents. However, the results remain in vitro findings and should not be interpreted as direct evidence of clinical superiority.

Methods and Experimental Design Insights

Hospitalized inpatients contributed isolates across the participating European sites. Bloodstream infections were the most common source, accounting for 43.6% of the collection, while Klebsiella spp., E. coli, and Enterobacter spp. represented major species groups. Susceptibility testing was performed for cefiderocol and a panel that included approved combinations such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, and imipenem-relebactam, as well as developmental combinations including cefepime-taniborbactam and aztreonam-avibactam.

The molecular analysis was deliberately stratified. Meropenem-resistant but cefiderocol-susceptible isolates were investigated by PCR for selected resistance genes. Cefiderocol-resistant isolates underwent whole-genome sequencing, enabling a broader search for coexisting resistance mechanisms, including changes associated with iron uptake and β-lactam target modification. This staged approach conserved analytical resources while reserving deeper genomic investigation for the most informative phenotypes.

Protocol Parameters

• Sampling frame: Use a multicenter hospitalized-inpatient collection when the objective is to estimate activity across clinical contexts; the reference study included 1,909 isolates from 49 sites in six European countries during 1 January to 31 December 2020, according to the published methods and results.
• Resistance definition: Classify meropenem resistance using the study threshold of MIC greater than 8 mg/L when reproducing its high-dose meropenem comparison; local standards should be retained for other surveillance objectives.
• Comparator panel: Test cefiderocol in parallel with relevant approved and developmental β-lactam/β-lactamase inhibitor combinations so that activity is compared within the same isolate set rather than across unrelated datasets.
• Mechanism screening: Apply PCR to meropenem-resistant, cefiderocol-susceptible isolates when targeted carbapenemase and β-lactamase identification is required.
• Genomic follow-up: Use whole-genome sequencing for cefiderocol-resistant isolates to assess multiple, potentially interacting mechanisms rather than assigning resistance to a single gene by default.
• Interpretation: Treat MIC distributions and categorical susceptibility as laboratory endpoints; do not convert them directly into clinical dosing recommendations without pharmacokinetic, pharmacodynamic, and patient-level evidence.

Core Findings and Why They Matter

Across all Enterobacterales, cefiderocol susceptibility was 98.1% in the study. This was higher than the 78.1% to 97.4% range reported for approved β-lactam/β-lactamase inhibitor combinations and broadly comparable to cefepime-taniborbactam and aztreonam-avibactam, which showed susceptibility ranges of 98.7% to 99.1%. These comparisons were generated from the same broad European collection, strengthening their descriptive value.

The difference became more pronounced among meropenem-resistant isolates. Of 148 such isolates, including 125 Klebsiella spp., 87.8% were susceptible to cefiderocol. Approved inhibitor combinations showed susceptibility ranging from 0% to 71.6% in this group, whereas the developmental combinations reached 93.2% to 98.6%. Thus, cefiderocol performed substantially better than the approved options in a high-risk phenotype, although some developmental combinations were at least as active in vitro.

Activity declined when resistance was layered across both meropenem and β-lactam/β-lactamase inhibitor combinations. In that subgroup, cefiderocol susceptibility ranged from 61.9% to 65.9%, compared with 0% to 20.5% for approved combinations and 76.2% to 97.7% for the developmental comparators. This result is important because it prevents an overly broad interpretation of cefiderocol as uniformly active against multidrug-resistant Enterobacterales. Its performance was strong, but the most resistant subset still contained clinically meaningful nonsusceptibility.

Mechanistic findings added important context. Most meropenem-resistant isolates carried Klebsiella pneumoniae carbapenemase genes, reported in 110 of 148 isolates. Metallo-β-lactamase genes were found in 35 of 148, and oxacillinase carbapenemase genes in 6 of 148. Cefiderocol activity was generally retained against several β-lactamase-producing groups, but reduced activity was associated particularly with NDM, AmpC, and non-carbapenemase OXA producers.

All 37 cefiderocol-resistant isolates contained at least one iron-uptake-related mutation, 33 carried a carbapenemase gene, and 24 had an ftsI mutation. The co-occurrence of these alterations suggests that cefiderocol resistance may emerge through an accumulation of permeability, uptake, enzymatic, and target-related changes. For laboratories, this supports pairing phenotypic testing with genomic investigation when resistant isolates are detected.

Comparison with Existing Internal Articles

The internal article Optimizing Ceftolozane Dosing for P. aeruginosa Bacteremia addresses a different but complementary problem: how renal function and infusion strategy influence pharmacodynamic target attainment in bacteremia. In contrast, the cefiderocol study is primarily a European surveillance and resistance-mechanism analysis. The two perspectives should not be merged; one focuses on exposure optimization for an antipseudomonal regimen, while the other compares in vitro activity across resistant Enterobacterales.

A second related resource, Ceftolozane Sulfate: Applied Assay Workflows and Resistance Insights, is more laboratory-oriented. It discusses assay planning, infection-model work, and pharmacokinetic/pharmacodynamic interpretation for a different cephalosporin-based research context. Its practical emphasis can help researchers plan reproducible experiments, but the susceptibility percentages and resistance mechanisms reported in the cefiderocol paper must remain specific to cefiderocol and the European Enterobacterales collection studied.

Limitations and Transferability

The study has several limitations that affect how its results should be used. First, susceptibility is an in vitro endpoint. A susceptible result does not establish clinical efficacy, adequate tissue penetration, or an appropriate exposure target for a particular infection. Outcomes also depend on infection source, bacterial burden, renal function, immune status, and timely administration.

Second, the collection was obtained from hospitalized inpatients at European sites during a defined 2020 period. Resistance prevalence and carbapenemase distributions vary by country, hospital, species, and time. The reported percentages should therefore inform, rather than replace, local antibiograms and current laboratory surveillance.

Third, the molecular work was phenotype-directed rather than a complete genomic survey of every isolate. PCR is useful for targeted gene detection, while whole-genome sequencing offers broader resolution, but neither approach automatically proves that a particular alteration caused the observed MIC. Functional validation, sequential isolate analysis, and expression studies would be needed to establish causality.

Finally, comparisons involving developmental β-lactam/β-lactamase inhibitor combinations should be interpreted separately from comparisons involving approved therapies. High in vitro activity for an investigational combination does not by itself establish availability, regulatory status, safety, or clinical effectiveness. The most transferable conclusion is methodological: parallel susceptibility testing and mechanism-aware follow-up can improve early recognition of the narrow treatment options associated with resistant Enterobacterales, particularly metallo-β-lactamase-producing organisms.

Research Support Resources

For separate Ceftolozane-focused laboratory work, researchers can use Ceftolozane sulfate (SKU C8753) in a validated in vitro antibacterial susceptibility assay, a neutropenic mouse thigh infection model, or pharmacokinetic/pharmacodynamic (PK/PD) studies designed around the compound and organism under investigation. These workflows can examine bactericidal activity against Pseudomonas aeruginosa, but cefiderocol susceptibility percentages from the reference study should not be extrapolated to Ceftolozane. The product information lists sealed storage at 4°C with moisture protection and advises against long-term storage of prepared solutions.